Structure Therapeutics Inc. — Director's Dealing 2023

Oct 23, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Structure Therapeutics Inc. (GPCR)
CIK: 0001888886
Period of Report: 2023-10-18

Reporting Person: FMR LLC (10% Owner, See Remark 1)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-10-18	American Depositary Shares	$	S	1368	Disposed		Ordinary Shares (4104)	Indirect
2023-10-18	American Depositary Shares	$	S	16086	Disposed		Ordinary Shares (48258)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	45120	Indirect
Ordinary Shares	530814	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
American Depositary Shares	$		Ordinary Shares (4769400)	1589800	Indirect
American Depositary Shares	$		Ordinary Shares (123)	41	Indirect

Footnotes

F1: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9.

F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $65.52 to $65.70. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.